kyron.bio’s Post

EUROPACCESS - Your Pharma Partner is delighted to announce that our delegates have confirmed their presence at the BIO Conference in San Diego from June 3 - 6! We are thrilled to have such a prestigious cast representing us at one of the biggest events of the year: * Jonathan Chapper (CHAPPER healthcare) * Branko Huc (Lenis farmacevtika d.o.o.) * Corinne Truffault (Intsel Chimos - Laboratoire Pharmaceutique) * Nejc Klopcic (Lenis farmacevtika d.o.o.) * Jessica Fischer (ilapo International Ludwigs-Pharmaceuticals (Ludwigs- Arzneimittel)) * Helga Keidel (ilapo International Ludwigs-Pharmaceuticals (Ludwigs- Arzneimittel) If you're attending the conference, we would love to connect and arrange a meeting with our delegates. Let's discuss opportunities, innovations, and collaborations that can drive our industry forward. #EUROPACCESS #BIOConference #SanDiego2024 #BIO2024 #MarketAccess #EuropeanMarkets #ExpandedAccess

Excited for the Pharma CI Conference in Newark! I’ll be representing SI Insights at this year’s Pharma CI conference and am looking forward to connecting with fellow professionals. Here’s what you can expect from us: 🌍 Comprehensive Coverage of the Indian, African, and Southeast Asian pharma markets for your consulting and competitive intelligence (CI) needs. 🌎 Expertise in US and EU pharma markets for tailored CI projects. Whether you're looking for insights, collaboration, or new opportunities, I’d love to meet and discuss how SI Insights can support your pharma CI and consulting goals. Let’s connect! 👋 #PharmaCI #PharmaConsulting #CompetitiveIntelligence #SIInsights #PharmaMarkets #IndiaPharma #AfricanPharma #SoutheastAsiaPharma #USPharma #EUPharma #PharmaExpertise

📣The Inbeeo view from Swiss Biotech Day!📣 Christel Jansen and Vincenzo Straccia were representing the Inbeeo team at the Swiss Biotech Association Swiss Biotech Day congress recently as well as visiting nearby clients. We were  both amazed to see first-hand such a breadth of innovation coming from this global Life Sciences hub in the heart of Europe – both very exciting and humbling at the same time. Christel and I had the privilege of meeting with organisations at the beginning of their journeys as well as with leaders from global institutions that are improving lives for people around the world at scale. It was a truly inspirational few days! A further highlight was visiting the Roche Building 1 in Basel (thank you again for the snap Christel!😎).  Your team may be at the point of looking for further investor support, or beginning to consider reimbursement strategy or indeed life cycle optimization. Just as with the vision communicated at Swiss Biotech Day and the views from Building 1, Inbeeo can help you see the bigger picture and what is possible. Want to discuss further? Please don't hesitate to reach out! #marketaccess #drugpricing #pharmaceuticals

Really interesting report from SwedenBIO about the current status of the Swedish life science industry. Excellent job Maja Neiman and the team involved in preparing this! Just to highlight some of the stats - out of approximately 4000 registered life science companies in Sweden, more than half are based in the Stockholm/Uppsala region, showing its significance as a thriving hub for life science. It's also encouraging to see that of the 200 companies that responded to the barometer survey in 2023, about 50% were planning to increase investment in R&D and new product innovation as well as advertising and brand building over the next few years, and about 10% identified legal issues as a key focus in 2023/2024. I'm curious to see how these stats compare to other major commercial areas in Sweden. You can find the report below. #lifescienceindustry #pharma #biotech #sweden

🔍 Navigating the complexities of pharma deals? Join the 'Pharma Dealmakers Panel: Viewing the Challenges from Both Sides' at #Sachs_ELSF on February 29th, 2024, at the Hilton Zurich Airport Hotel. A deep dive into the intricacies of biopharma collaborations and negotiations. 🌐🤝 Chaired by: Sarah Holland, President of Swiss HLG & CBO, Cureteq AG - a Partex Company Panellists: Alessandra Polara, Senior Director, Global BD, F. Hoffmann-La Roche AG David Colpman, Director, Alpina Life Science Advisors Emin Fadillioglu, MD, CEO, Eczacıbaşı Topluluğu Pharmaceutical and Industrial Investment Co. Peter L. Braun, CEO, TargImmune Therapeutics AG Ulrich Wendt, Global Head Business Development Immunology & Inflammation, Sanofi Gain unparalleled insights into the challenges and strategies of pharma dealmaking from the perspectives of both biotech innovators and pharma giants. This panel is a must-attend for those looking to understand the dynamics of successful partnerships and investments in the rapidly evolving life sciences landscape. Don’t miss out on this opportunity to network with industry leaders and strategize for success. Register today at www.sachsforum.com/17elsf and be part of the conversation #inperson & #online during the Sachs Spring Life Sciences Week. #PharmaDealmakers #Biopharma #LifeSciences #StrategicPartnerships #InvestmentStrategies #BiotechInnovation #PharmaIndustry #SachsForum #Sachs_ELSF #SachsSpringLifeSciencesWeek #SSLSW

Collaboration: The powerful leverage in Drug Development BioArctic's post highlighting CEO Gunilla Osswald's revised perspective on AstraZeneca's 5R Framework for successful drug development is spot on. As a scientist with 12 years of experience leading Offspring Biosciences, a Tissue Analytics CRO, as well as previously working on the big pharma side overseeing outsourcing of research, I offer my take on this. Synergy through Collaboration: The Power of the 6th R Gunilla's insightful addition of a 6th "R" – Right Collaboration – to the existing 5R framework is a powerful recognition of the critical value CRO partnerships brings to drug development. Indeed, the CRO industry's tremendous expansion during the past 15 years is a direct reflection of the growing need for specialized expertise in today's complex drug development landscape. Beyond Execution: The Embedded Scientific Partner However, maximizing the value of these collaborations hinges on how they are structured and executed. This is where Gunilla Osswald's concept of "Right Collaboration" comes into play. My experience is that the ideal scenario involves the CRO functioning as a truly embedded scientific partner, actively involved in designing, executing, and evaluating studies that drives the projects forward to the next critical decision point. This collaborative approach stands in contrast to operative models for outsourcing where the CROs serve primarily as an extension of the pharma company's lab, executing tasks with limited input. BioArctic’s 6R framework, with its emphasis on Right Collaborations, paves the way for a more symbiotic relationship which leverages the strengths of both pharma and CRO for an accelerated and successful drug development progress. A Shared Journey As scientists and industry professionals, both within pharma and CROs, we share a common goal: advancing the development of safe and effective drugs that brings true value to our common client – the patients. Let's unlock the power of true collaborations, as outlined in the 6R framework, to turn this vision into reality. What do you think? Share your experiences from collaborative CRO partnerships in the comments! #Collaboration #DrugDevelopment https://lnkd.in/dfPpTRgc https://lnkd.in/dgPX22aV

How can we strengthen the ROI of incorporating digital biomarkers in drug development trials and accelerate its adoption… looking forward to hearing the sessions today and sharing the insights! #DigitalBiomarkersSummit #medidata #clinicalinnovation

Insightful discussion on the value of partnerships at Executive Insights 2024 Emphasizing that partnerships are critical for successful drug development, especially for small companies like BioArctic that rely on collaborations, Gunilla Osswald, BioArctic CEO, was one of the speakers at the Executive Insights 2024 conference hosted by Cytel, DNB, and Flerie. Osswald values partners who are truly interested in working together cooperatively to achieve strong relationships and added a sixth "R" to the classic 5R concept in pharma negotiations - focusing on the significance of relationships and their ability to advance innovation. The six Rs: - Right target - Right patient population - Right dose and exposure - Right study design - Right safety - Right collaborations

We can't wait to hear you facilitate this discussion, Amy Mahery. Such a timely topic on digital and AI innovation in pharma. Learn more here: https://bit.ly/47EjT5E

Welcome to the NLSDays 2024 in Malmö! This significant event, the Nordic Life Science Days 2024, will return to Malmö, Sweden, on 18-19 September. We will be exhibiting at this great event! Nubilaria, stand number C04. We are also a presenter at conference. Date: 18 September 2024 Time: 14:15 Location: Main Hall Our colleagues Franco Schiannini and Erich Cavicchiolo are excited to have you at this prestigious event and are looking forward to your presence! https://lnkd.in/d4VHZKyZ #clinicalresearch #healthcaredata #healthcareit #healthcaresoftware #data #healthcare #pharmaceuticals #digitalhealthcare #pharmaceuticaltechnology #clinicalresearch #clinicaltrials #digitalhealth #healthtechnology #healthtech #clinicalresearch #clinical #cro #clinicaldata #clinicaltrialmanagement #clinicalstudies #clinicaldataplatforms #remotehealthcare #remotehealth #clinicaloperations #clinicaldevelopment #clinicaloperations #clinicaldata #remotemonitoring #datamanagementplatform #datamanagement #pharma #lifescience #rwe #rwd #epro #sops #etmf #edc #sdv #edc #cra #rtsm #sae #uat #gcp #qa #ecoa #iwrs #esource #econsent #decentralizedtrials #decentralizedstudies